Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity
Authors
Mark Fesler
Jeff Porter Sharman (ORCID: https://orcid.org/0000-0001-5611-6115)
Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity
Mark Fesler, Jeff Porter Sharman, Suchitra Sundaram, Sami Ibrahimi et al.
Journal
Blood
Topics
CAR-T cell therapy research
article
Outpatient administration of epcoritamab monotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Results from EPCORE NHL-6 by race and ethnicity
Mark Fesler, Jeff Porter Sharman, Suchitra Sundaram, Sami Ibrahimi, Fernando Vargas Madueno, J. Erika Haydu, Kristin Conte, Bradley W. Lash, David Andorsky, Christian Winther Eskelund, Kojo Osei-Bonsu, Alexander P. Boardman, John Hrom, Seema Naik, Yang Bai, Christina Lee, Eric Lee, Ralph V. Boccia, Mitul Gandhi, A Torres, Rakhee Vaidya
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Atrium Health Wake Forest Baptist (US), Lehigh Valley Hospital-Pocono (US), Memorial Sloan Kettering Cancer Center (US), AbbVie (United States) (US), Moffitt Cancer Center (US), St. Luke's Hospital (US), Hattiesburg Clinic (US), Stony Brook Medicine (US), Auxilio Mutuo Hospital (PR), Center for Cancers and Blood Disorders (US), Rocky Mountain Cancer Centers (US), Compassionate Cancer Care (US), Willamette Valley Cancer Institute and Research Center (US), Forrest General Hospital (US), Center for Cancer Research (US), Georgia Cancer Specialists (US), Genmab (Denmark) (DK), University of Oklahoma Health Sciences Center (US), Penn State Milton S. Hershey Medical Center (US), Icahn School of Medicine at Mount Sinai (US)